Xevudy, generically known as sotrovimab, is a monoclonal antibody medication designed specifically for the treatment of COVID-19. It is engineered to bind to the spike protein of SARS-CoV-2, the virus responsible for COVID-19, thereby neutralizing the virus and preventing it from entering human cells. Xevudy is typically administered through intravenous infusion and is intended for use in individuals who have contracted COVID-19 and are at risk of developing severe illness, but who are not yet hospitalized. This includes patients who are elderly, immunocompromised, or have underlying health conditions. By targeting the early stages of infection, Xevudy aims to reduce the severity of the disease and prevent hospitalizations. It is important to note that the effectiveness and availability of Xevudy may vary based on evolving clinical evidence and the emergence of new variants of the virus.